Breast cancer can be categorised according to molecular subtype and stage of disease. Advanced breast cancer (aBC) describes both locally advanced and metastatic disease. Around 75% of aBC patients have hormone receptor-positive (HR+) tumours, with over 70% of these patients also having human epidermal growth factor receptor 2-negative (HER2−) tumours.1

Targeting hormone receptors via endocrine therapy has long been a mainstay of treatment for HR+/HER2− aBC. However, endocrine monotherapy typically only delays disease progression for around 1 year.2

The development of newer targeted therapies, such as CDK4/6 inhibitors, has widened options for treatment; in combination with endocrine therapy, they can improve clinical outcomes.2


CDK4/6, cyclin-dependent kinases 4/6; HR+/HER2−, hormone receptor-positive/human epidermal growth factor receptor 2-negative. 


  1. El Sayed R, et al. Front Oncol 2019;9:510.
  2. Matutino A, et al. Curr Oncol 2018;25(Suppl 1):S131–S141.
Rate this content: 
Average: 5 (1 vote)
UK | August 2022 | 231465

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]